HRSA auditors have started asking for discharge logs
Several hospitals learned the hard way this spring that HRSA’s 2026 audit teams now want detailed discharge prescription data. A 340B compliance manager at a large DSH hospital in Indiana told me her March audit request included a new line item: “Documentation supporting outpatient status at time of 340B drug administration or dispensing for discharge prescriptions.” That language didn’t appear in her 2024 or 2025 audit summaries. The focus is unmistakable, HRSA’s pharmacy auditors are zeroing in on how inpatient medications, often purchased at GPO prices, are converted or replaced with 340B drugs during transitions to discharge or home-going prescriptions.
This issue isn’t hypothetical. Hospitals still wrestle with separating inpatient dispensing systems from outpatient capture points. When a patient fills a “discharge med to bed” prescription before heading home, the drug looks outpatient from a workflow perspective. But if the dose originated from inpatient inventory or the patient’s status change lagged in the EHR, that fill can easily violate 340B eligibility. HRSA is actively targeting that weak link in 2026 audits.
Why inpatient-to-outpatient conversions now trigger findings
HRSA updated its 340B audit protocols in late 2025 after multiple OIG reports faulted the agency for inconsistency around mixed-use drugs. The new version expanded “covered outpatient drug” verification and explicitly flagged transitional care prescriptions. That matters because hospitals often restock their automated dispensing cabinets with GPO-priced medications but bill those drugs as outpatient once the patient is discharged. The 340B statute under Section 340B(a)(4) doesn’t allow 340B pricing for inpatient drugs, and HRSA has reiterated the separation rule in every memo since 2012. What’s different now is enforcement. 2026 audits are probing those crossover points through data requests and EHR deep-dives.
Today’s HRSA auditors don’t just ask for the med-use record, they want proof of patient status at the exact moment of dispense or administration. Some hospitals rely on a “status change report” that timestamps when the patient became outpatient. That works only if the pharmacy system tags orders with that transition data. HRSA has rejected logs showing post-discharge conversions that lacked an order rewrite or separate outpatient encounter. If the prescription label still links to an inpatient admission number, it’s a finding waiting to happen.
The compliance trap hidden in “meds to beds” programs
Pharmacy directors love discharge fill programs for good reason: they improve adherence and recapture lost revenue. Under 340B, they can also generate healthy margins, if everything lines up legally. The danger is in the operational handoff. Hospital pharmacists often prep discharge fills using inpatient stock, then reconcile quantities later in the dispensing system. Operationally efficient. Compliance-wise? A mess. HRSA’s stance hasn’t budged: a drug bought under GPO can’t later be replaced with a 340B equivalent. A single mislabeled NDC can become a payback order covering hundreds of scripts if controls look sloppy.
In 2025 HRSA cited a children’s hospital in Texas after discovering more than 800 discharge prescriptions had been filled from inpatient stock before outpatient conversion. The entity argued those were outpatient discharges written by credentialed clinic physicians. HRSA said no, those fills occurred under an inpatient episode. Result: $91,000 in repayments to manufacturers and a two-year corrective action plan.
Technology is now the only realistic safeguard. Hospitals building barcode-based restocking and drug-source tracking, where each physical transaction ties to the patient’s financial status at dispense, are surviving audits. Manual logs, spreadsheets, even signed paper substitutions no longer pass. HRSA routinely requests Epic and Cerner data extracts by encounter type and runs its own counts to see where inpatient drugs were coded as outpatient fills. And yes, they will find them.
Where HRSA is heading with oversight
Behind these tougher audits is HRSA’s growing frustration at how broadly hospitals define “outpatient.” The 2025 FAQ updates on patient definition kept inpatient-to-outpatient transitions deliberately vague, giving HRSA room to maneuver. The current trend makes it clear: expect tighter guidance, not leniency. Many compliance leaders anticipate discharge-prescription guidance before the end of 2026, clarifying how “observation” or “same-day discharge” fits into outpatient eligibility. Until that happens, clinical documentation remains the proof standard, physicians and pharmacists need synchronized records down to the minute. Literally.
Manufacturers are sharpening their focus too. Several expanded their 340B ESP verification criteria to flag claims from hospital outpatient pharmacies physically located on inpatient campuses. When a discharge prescription moves through the same wholesaler account used for inpatient purchases, some ESP systems automatically trigger exclusions. Hospitals that fail to separate 340B wholesaler hierarchies see conflicting data in ESP reports, and HRSA now interprets those disputes as red flags for program integrity. That’s why every covered entity with an on-campus outpatient pharmacy should be cross-checking encounter types and ship-to IDs quarterly. If not more often.
How to fix your discharge prescription process before HRSA does
The compliance fix is straightforward in theory but takes serious design work. Step one: lock down when the patient becomes outpatient in your ADT feed and let that status drive pharmacy order entry. If a physician writes a discharge prescription while the patient remains inpatient, that order must wait until the status flips. Step two: confirm outpatient orders pull from 340B-eligible inventory, segregation must be real, physical or virtual. If your med-to-bed cabinet is restocked from inpatient supply, treat every fill as a GPO or WAC purchase. Step three: document, document, document. Keep a signed reconciliation log affirming which discharge fills were 340B-eligible. HRSA will accept sampled attestations backed by source data but not narrative policies without timestamps.
Some hospitals now use third-party verification layers between EHR and split-billing systems to create a “discharge capture feed.” I’ve seen it work; a West Coast DSH hospital built a rule that blocked any prescription lacking an official discharge timestamp marked “outpatient.” Disputed claims dropped by 72% in their 2025 self-audit. It slowed pharmacists down, but that’s cheaper than a repayment demand.
HRSA hasn’t yet levied civil penalties specifically for this category, though the 2026 enforcement manual authorizes them if a hospital knowingly diversifies inpatient drugs as 340B. That’s a serious shift. If your compliance officer brushed this off two years ago, it’s time for a different conversation. HRSA’s scripts are moving faster than many hospital policies, and inpatient-to-outpatient conversion is still the biggest blind spot in mixed-use pharmacy operations. Look, if you’re waiting for HRSA to issue guidance before tightening your process, you’re already behind.